Compare NWTG & LABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWTG | LABT |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 5.3M |
| IPO Year | 2022 | 2026 |
| Metric | NWTG | LABT |
|---|---|---|
| Price | $1.11 | $0.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 64.8K | ★ 611.3K |
| Earning Date | 11-12-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.09 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,135,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $104.02 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 136.14 | N/A |
| 52 Week Low | $0.70 | $0.92 |
| 52 Week High | $1.97 | $6.85 |
| Indicator | NWTG | LABT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 27.99 |
| Support Level | N/A | N/A |
| Resistance Level | N/A | $2.50 |
| Average True Range (ATR) | 0.00 | 0.23 |
| MACD | 0.00 | -0.11 |
| Stochastic Oscillator | 0.00 | 2.21 |
Newton Golf Co Inc is a technology-forward golf company engaged in designing, manufacturing, and selling performance golf equipment, including premium golf shafts and putters, and focuses on developing technology-driven golf products intended to enhance player performance. The company sells its products through e-commerce, distributors, wholesale customers, including pro-shops at golf courses and off-course retailers, sporting goods retailers, online retailers, third-party distributors, and through Club Champion Golf.
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.